Search
Snail, unspecified
go.drugbank.com/drugs/DB14245ApprovedInvestigationalSnail, unspecified is an animal extract used in some OTC (over-the-counter) products. It is not an approved drug.
Ensitrelvir
go.drugbank.com/drugs/DB18834ApprovedInvestigationalEnsitrelvir is under investigation in clinical trial NCT05605093 (Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE): Shionogi Protease Inhibitor (Ensitrelvir)).
Cerulenin
go.drugbank.com/drugs/DB01034ExperimentalIn fatty acid synthesis, reported to bind in equimolar ratio to b-keto-acyl-ACP synthase. In sterol synthesis, inhibits HMG-CoA synthetase activity. … It is also shown to inhibit feeding and induce dramatic weight loss in mice. It is found naturally in the Cephalosporium caerulensfungus.
Andrographolide
go.drugbank.com/drugs/DB05767InvestigationalThe herb has an extensive history of use in TCM for the treatment of upper respiratory tract infections and other inflammatory and infectious diseases. … Andrographolide (HMPL-004) is a botanical product extracted from a herb that occurs naturally in China.
Ferumoxides
go.drugbank.com/drugs/DB09508ApprovedCategories: Compounds used in a research, industrial, or household settingLaropiprant
go.drugbank.com/drugs/DB11629ApprovedWithdrawnLaropiprant is an ingredient in the EMA-withdrawn product Pelzont.
Ticarcillin
go.drugbank.com/drugs/DB01607ApprovedVet approvedWithdrawnAn antibiotic derived from penicillin similar to carbenicillin in action.
Calcipotriol
go.drugbank.com/drugs/DB02300ApprovedInvestigationalCalcipotriol (INN) or calcipotriene (USAN) is a sythetic derivative of calcitriol or Vitamin D.
Plozalizumab
go.drugbank.com/drugs/DB12520InvestigationalPreclinical studies suggest that CCR2 plays an important role in the trafficking of monocytes and macrophages to sites of inflammation. … The recruitment of macrophages to the arterial wall is believed to be a critical step in the development of atherosclerosis.
Sinapultide
go.drugbank.com/drugs/DB11332ApprovedWithdrawn[L2504] Windtree is currently developing aerosolized KL4 surfactant to treat RDS in premature infants, and thereafter, to potentially address a range of indications in neonatal, pediatric and adult … [L2502] Windtree Therapeutics plans a phase III trial for Respiratory distress syndrome in 2018.